Cocrystal Pharma Announces Last Subject Dosed in Phase 1b Human Challenge Study Evaluating CDI-988 for Norovirus Prevention and TreatmentGlobeNewsWire · Sep 9, 2026
Cocrystal Pharma Appoints Carol Brosgart, MD to its Board of DirectorsGlobeNewsWire · Aug 17, 2026
Cocrystal Pharma Announces $5 Million Private Placement with OPKO HealthGlobeNewsWire · Aug 3, 2026
Financial Contrast: Cocrystal Pharma (NASDAQ:COCP) vs. Zevra Therapeutics (NASDAQ:ZVRA)Defense World · Aug 3, 2026Cocrystal Pharma, Inc. (COCP) is a biotechnology firm dedicated to researching and advancing antiviral treatments for severe and/or persistent viral illnesses. The company leverages structure-based technologies to create new antiviral medications, primarily focusing on infections caused by the hepatitis C virus (HCV), influenza, coronaviruses, and noroviruses. Its current pipeline includes CC-31244, a non-nucleoside polymerase inhibitor for HCV, which has successfully completed Phase IIa clinical trials.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 13, 2026 | -$0.17 | -$0.23 | Miss |
| May 15, 2026 | -$0.15 | -$0.17 | Miss |
| Mar 31, 2026 | -$0.18 | -$0.17 | Beat |
| Nov 14, 2025 | -$0.22 | -$0.19 | Beat |
| Aug 14, 2025 | -$0.30 | -$0.20 | Beat |
| May 15, 2025 | -$0.52 | -$0.23 | Beat |